预约演示
EC approves Merck’s KEYTRUDA regimen for NSCLC treatment
2024-03-29
临床3期临床结果上市批准
With the EC approval, Merck’s KEYTRUDA treatment can be marketed for NSCLC treatment across all 27 EU member states. Credit: Copyright © 2024 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.
The European CommissioMerck) hKEYTRUDAved Merck’s KEYTRUDA regimen foNSCLCating adult patients with resectable non-small cell lung cancer (NSCMerck & Co., Inc.recurrence risk.
This approval follows the Committee for MeMerckal KEYTRUDA for Human Use positive recommendation in resectable non-small cell lung cancer (NSCLC)
KEYTRUDA, indicated for usage in combination with platinum-containing chemotherapy, will serve as a neoadjuvant treatment and continue as monotherapy for adjuvant treatment.
KEYTRUDA decision is based on the double-blind, randomised Phase III KEYNOTE-671 trial outcomes.
The trial enrolled 797 patients with event-free survival (EFS) and overall survival (OS) as the dual primary endpoints of the trial.
See Also:
Abivax gets grant for antitumor pharmaceutical combination for cancer treatment
At a median follow-up of 29.8 months, results showed a 28% reduction in the mortality risk and a 41% decrease in the disease recurrence, progression, or mortality risk in patients treated with the KEYTRUDA-based regimen.
Atea Pharmaceuticalstients receiving KEYTRUDA wascovid-19 higher than for those on the chemotherapy-placebo regimen, with the former not yet reached versus 52.4 months for the latter.
With this approval, the KEYTRUDA regimen can be marketed for this indication across all 27 EU member states, as well as in Liechtenstein, Iceland, Norway, and Northern Ireland.
This marks the sixth NSCLC indication for KEYTRUDA in the EU, contributing to its 27 overall indications in the region.KEYTRUDA
Merck Research Laboratories global clKEYTRUDAevelopment, oncology senior vice-president and head Marjorie Green said: “The approval of the first anti-PD-1/L1 therapy as part of a treatment regimen in Europe for the neoadjuvant followed by adjuvant treatment of resectable NSCLC based on positive overall survival results demonstrates our continued progress to advance treatments in earlier stages of lung cancer.
“We are eager to build oKEYTRUDAomentum as we plan to seek additional approvals of this regimen around the world, and to work together with the cancer community to help drive earlier diagnoses of lung cancer, an urgent need.”
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。